Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Other Working Capital Changes: 2017-2024

Historic Other Working Capital Changes for Solid Biosciences (SLDB) over the last 7 years, with Dec 2024 value amounting to -$104,000.

  • Solid Biosciences' Other Working Capital Changes rose 78.06% to -$104,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $2.4 million, marking a year-over-year increase of 240.92%. This contributed to the annual value of $2.4 million for FY2024, which is 4350.23% up from last year.
  • Solid Biosciences' Other Working Capital Changes amounted to -$104,000 in Q4 2024, which was down 110.47% from $993,000 recorded in Q3 2024.
  • In the past 5 years, Solid Biosciences' Other Working Capital Changes ranged from a high of $22.2 million in Q4 2020 and a low of -$11.4 million during Q2 2022.
  • Its 3-year average for Other Working Capital Changes is -$737,000, with a median of -$273,000 in 2024.
  • In the last 5 years, Solid Biosciences' Other Working Capital Changes skyrocketed by 496.42% in 2020 and then tumbled by 353.53% in 2021.
  • Solid Biosciences' Other Working Capital Changes (Quarterly) stood at $22.2 million in 2020, then crashed by 113.74% to -$3.0 million in 2021, then plummeted by 245.91% to -$11.4 million in 2022, then skyrocketed by 103.88% to -$474,000 in 2023, then soared by 78.06% to -$104,000 in 2024.
  • Its last three reported values are -$104,000 in Q4 2024, $993,000 for Q3 2024, and -$442,000 during Q2 2024.